Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 10, 2004, Pages 1472-1474

  Dodel, R C ^a   Du, Y ^b   Depboylu, C ^a   Hampel, H ^c   Frolich L ^d   Haag, A ^e   Hemmeter, U ^e   Paulsen, S ^f   Teipel, S J ^c   Brettschneider, S ^c   Spottke, A ^a   Nolker C ^a   Moller H J ^c   Wei, X ^b   Farlow, M ^b   Sommer, N ^e   Oertel, W H ^e  

^a UNIVERSITY OF BONN   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; DONEPEZIL; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODY FORMATION; COGNITION DISORDERS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 4644275963     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.033399     Document Type: Article

References (15)

1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7.
2. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001;98(15):8850-5.
3. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408(6815):982-5.
4. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5(5):452-7.
5. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003;2(4):215-20.
6. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-19.
7. Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997;94(1-3):213-22.
8. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52(2):253-6.
9. Du Y, Wei X, Gao F, et al. Human anti-Abeta antibodies block Abeta fibril formation and prevent Abeta-induced neurotoxicity. Brain 2003;126:1-5.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
11. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001;57(5):801-5.
12. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295(5563):2264-7.
13. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52.
14. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-8.
15. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24(3):458-62.